These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37188188)

  • 41. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
    Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
    Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
    Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
    Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia.
    Wang L; Mou H; Hou X; Liao Q
    Front Oncol; 2023; 13():1126769. PubMed ID: 36998453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
    Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
    Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.
    Marmorino F; Boccaccino A; Germani MM; Falcone A; Cremolini C
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
    Germani MM; Carullo M; Boccaccino A; Conca V; Masi G
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
    Damilakis E; Mavroudis D; Sfakianaki M; Souglakos J
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32268531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
    Xu H; Hong Z; Xu M; Kong Y; Ma Y; Shan C; Xing P; Zhang L
    Front Immunol; 2022; 13():926740. PubMed ID: 35874658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.
    Zhong L; Liu X; Li Z; Zhang X; Wang Y; Peng W
    Front Oncol; 2021; 11():783158. PubMed ID: 35096582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy for the treatment of colorectal cancer.
    Lumish MA; Cercek A
    J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
    Zhang JW; Deng YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
    Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
    Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 56. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
    Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
    BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.
    Wang T; Shao Q; Xiao C; Liu L
    Front Oncol; 2023; 13():1124730. PubMed ID: 36998454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report.
    Yang J; Bi F; Gou H
    Onco Targets Ther; 2021; 14():2555-2561. PubMed ID: 33880034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.